Therapeutic Vaccines against Human and Rat Renin in Spontaneously Hypertensive Rats

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Qiu, Zhihua ^a   Chen, Xiao ^a   Zhou, Yanzhao ^a   Lin, Jibin ^a   Ding, Dan ^a   Yang, Shijun ^a   Chen, Fen ^a   Wang, Min ^a   Zhu, Feng ^a   Yu, Xian ^a   Zhou, Zihua ^a   Liao, Yuhua ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTYLTHREONYLGLYCYLSERYLALANYLASPARAGINYLLEUCINE; ASPARTYLTHREONYLGLYCYLSERYLSERYLASPARAGINYLVALINE; FREUND ADJUVANT; KEYHOLE LIMPET HEMOCYANIN; PEPTIDE VACCINE; RENIN; THREONYLISOLEUCYLHISTIDINYLTYROSYLGLYCYLSERYLGLYCYLLYSYLVALYLLYSINE; THREONYLLEUCYLARGINYLTYROSYLSERYLTHREONYLGLYCYLTHREONYLVALYLSERINE; UNCLASSIFIED DRUG; VALSARTAN; VALYLASPARTYLTHREONYLGLYCYLALANYLSERYLTYROSINE; VALYLASPARTYLTHREONYLGLYCYLTHREONYLSERYLTYROSINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGENICITY; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CATALYSIS; CONTROLLED STUDY; CROSS REACTION; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; HYDROPHILICITY; HYPERTENSION; MALE; NONHUMAN; PEPTIDE SYNTHESIS; RADIOIMMUNOASSAY; RAT; TRANSMISSION ELECTRON MICROSCOPY; VACCINATION;

AMINO ACID SEQUENCE; ANGIOTENSIN II; ANIMALS; ANTIBODY SPECIFICITY; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CATALYTIC DOMAIN; CROSS REACTIONS; HUMANS; IMMUNOGLOBULIN G; RATS; RATS, INBRED SHR; RENIN; VACCINATION; VACCINES, SUBUNIT;

ANIMALIA; RATTUS;

EID: 84879334310     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066420     Document Type: Article

References (33)

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, et al. (2005) Global burden of hypertension: analysis of worldwide data. Lancet 365: 17-23.
2. Bachmann MF, Dyer MR, (2004) Therapeutic vaccination for chronic diseases: a new class of drugs in sight. Nat Rev Drug Discov 3: 81-88.
3. Inagami T (1989) Structure and function of renin. J Hypertens Suppl 7: S3-S8.
4. Brown MJ, (2009) Success and failure of vaccines against renin-angiotensin system components. Nat Rev Cardiol 6: 639-647.
5. Zhu F, Zhou ZH, Liao YH, (2008) The renin-angiotensin system and therapeutic vaccines for hypertension. Curr Opin Investig Drugs 9: 286-294.
6. Goldblatt H, Haas E, Lamfrom H, (1951) Antirenin in man and animals. Trans Assoc Am Physicians 64: 122-125.
7. Michel JB, Guettier C, Philippe M, Galen FX, Corvol P, et al. (1987) Active immunization against renin in normotensive marmoset. Proc Natl Acad Sci U S A 204: 281-288.
8. Michel JB, Sayah S, Guettier C, Nussberger J, Philippe M, et al. (1990) Physiological and immunopathological consequences of active immunization of spontaneously hypertensive and normotensive rats against murine renin. Circulation 81: 1899-1910.
9. Tong L, Pav S, Lamarre D, Pilote L, LaPlante S, et al. (1995) High Resolution Crystal Structures of Recombinant Human Renin in Complex with Polyhydroxymonoamide Inhibitors. J Mol Biol 250: 211-222.
10. Sali A, Veerapandian B, Cooper JB, Foundling SI, Hoover DJ, et al. (1989) High-resolution X-ray diffraction study of the complex between endothiapepsin and an oligopeptide inhibitor: the analysis of the inhibitor binding and escription of the rigid body shift in the enzyme. EMBO J 8: 2179-2188.
11. Bouhnik J, Galen FX, Menard J, Corvol P, Seyer R, et al. (1987) Production and characterization of human renin antibodies with region-oriented synthetic peptide. J Biol Chem 262: 2913-2918.
12. Ben-Yedidia T, Arnon R, (1997) Design of peptide and polypeptide vaccines. Curr Opin Biotechnol 8: 442-448.
13. Haste Andersen P, Nielsen M, Lund O, (2006) Prediction of residues in discontinuous B-cell epitopes using protein 3D structures. Protein Sci 15: 2558-2567.
14. Kanduc D, (2009) Epitopic peptides with low similarity to the host proteome: towards biological therapies without side effects. Expert Opin Biol Ther 9: 45-53.
15. Lucchese A, Mittelman A, Lin MS, Kanduc D, Sinha AA, (2004) Epitope definition by proteomic similarity analysis: identification of the linear determinant of the anti-Dsg3 MAb 5H10. J Transl Med 2: 43.
16. Stufano A, Kanduc D, (2009) Proteome-based epitopic peptide scanning along PSA. Exp Mol Pathol 86: 36-40.
17. Evin G, Carlson WD, Handschumacher M, Novotný J, Matsueda GR, et al. (1986) Study of the antigenic determinants of human renin. Hypertension 8: II72-II77.
18. Evin G, Galen FX, Carlson WD, Handschumacher M, Novotný J, et al. (1988) Characterization of five epitopes of human renin from a computer model. Biochemistry 27: 156-164.
19. Galen FX, Evin G, Carelli C, Bouhnik J, Michel JB, et al. (1987) Production and characterization of human renin antibodies prepared with synthetic immunogens. J Hypertens Suppl 5: S11-S14.
20. Sen S, Smeby RR, Bumpus FM, (1972) Renin in Rats with Spontaneous Hypertension. Circ Res 31: 876-880.
21. Bagby SP, McDonald WJ, Mass RD, (1979) Serial renin-angiotensin studies in spontaneously hypertensive and Wistar-Kyoto normotensive rats. Transition from normal- to high-renin status during the established phase of spontaneous hypertension. Hypertension 1: 347-354.
22. Ferrer I, Boada Rovira M, Sánchez Guerra ML, Rey MJ, Costa-Jussá F, (2004) Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 14: 11-20.
23. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, et al. (2003) Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 9: 448-452.
24. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, et al. (2003) Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61: 46-54.
25. Feng Zhu, Yuhua Liao, (2008) Therapeutic renin-angiotensin vaccines for the treatment of hypertension. Drugs of the Future 33: 1-9.
26. Michel JB, (2004) Renin-angiotensin vaccine: old story, new project 'efficacy versus safety'. Clin Sci (Lond) 107: 145-147.
27. Lemere CA, Maier M, Peng Y, Jiang L, Seabrook TJ, (2007) Novel Abeta immunogens: is shorter better? Curr Alzheimer Res 4: 427-436.
28. Feldt S, Batenburg WW, Mazak I, Maschke U, Wellner M, et al. (2008) Prorenin and Renin-Induced Extracellular Signal-Regulated Kinase 1/2 Activation in Monocytes Is Not Blocked by Aliskiren or the Handle-Region Peptide. Hypertension 51: 682-688.
29. Batenburg WW, de Bruin RJ, van Gool JM, Müller DN, Bader M, et al. (2008) Aliskiren-Binding Increases the Half Life of Renin and Prorenin in Rat Aortic Vascular Smooth Muscle Cells. Arterioscler Thromb Vasc Biol 28: 1151-1157.
30. Reudelhuber TL, (2010) Prorenin, Renin, and Their Receptor Moving Targets. Hypertension 55: 1071-1074.
31. Gironacci MM, Adamo HP, Corradi G, Santos RA, Ortiz P, et al. (2011) Angiotensin (1-7) Induces Mas Receptor Internalization. Hypertension 58: 176-181.
32. Wood JM, Maibaum J, Rahuel J, Grütter MG, Cohen NC, et al. (2003) Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 308: 698-705.
33. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, et al. (2012) Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 367: 2204-2213.